Epcoritamab Regimen Yields Remission in High-Risk R/R Follicular LymphomaJune 7th 2023
The responses to epcoritamab plus rituximab/lenalidomide for patients with relapsed/refractory follicular lymphoma appear comparable between those with and without disease progression within 24 months of first-line chemotherapy in the phase 1/2 EPCORE NHL-2 trial.
OS and EFS Improved With Neoadjuvant Chemotherapy/Carboplatin for Locally Advanced TNBCDecember 10th 2022
Patients with operable, locally advanced triple-negative breast cancer experienced notable improvements in survival following treatment with neoadjuvant carboplatin plus sequential taxane-anthracycline neoadjuvant chemotherapy.
Neoadjuvant Combination of Nivolumab/Ipilimumab Yields High Major Pathologic Response Rate in dMMR Colon CancerSeptember 12th 2022
Patients with mismatch repair deficient (dMMR) colon cancer experienced a high rate of major pathologic complete response following treatment with nivolumab and ipilimumab for 4 weeks.
Nivolumab and Ipilimumab Plus Chemotherapy Yields Consistent Survival Benefit in Metastatic NSCLC at 3-Year Follow-UpJune 6th 2022
At a minimum follow-up of 3 years, an improvement in overall survival was seen in patients with metastatic non–small cell lung cancer treated with nivolumab and ipilimumab in combination with chemotherapy.
Targeting CD117 With JSP191, TBI, and Fludarabine Appears Safe and Efficacious in MDS/AMLApril 29th 2022
JSP191 plus fludarabine and low-dose total body radiation to target CD117 was a safe strategy to induce facilitation of full donor myeloid chimerism and clear minimal residual disease in older patients with myelodysplastic syndrome and acute myeloid leukemia receiving non-myeloablative allogenic hematopoietic cell transplantation.
Addition of Best Supportive Care to Pembrolizumab Significantly Improved Survival for Advanced HCCJanuary 21st 2022
Patients with advanced hepatocellular carcinoma achieved a statically significant and clinically meaningful survival benefit following treatment with pembrolizumab and best supportive care in the second line.
More Favorable Safety Profile of Acalabrutinib Vs Ibrutinib Validated for CLLDecember 14th 2021
A post-hoc analysis of a phase 3 trial presented at 2021 ASH indicate that acalabrutinib may be favorable in terms of toxic burden and cardiovascular-related events when compared against ibrutinib for treating chronic lymphocytic leukemia.
Patient Race Doesn’t Significantly Impact Pathological CR After Neoadjuvant Therapy for Breast CancerDecember 10th 2021
Research from the 2021 San Antonio Breast Cancer Symposium suggests pathologic complete response and event-free survival were not significantly impacted by race for women with high-risk breast cancer who underwent targeted neoadjuvant chemotherapy.
Nivolumab/Cabozantinib Combo Yielded Efficacy in Renal Cell Carcinoma Regardless of NephrectomySeptember 17th 2021
Patients with renal cell carcinoma experienced a better overall survival when treated with nivolumab plus cabozantinib regardless of whether or not they underwent a nephrectomy previously.
First-in-Human Trial of CLN-081 in EGFR ex 20+ NSCLC Shows Early PromiseJune 4th 2021
A phase 1 trial of the investigational agent CLN-081 indicates antitumor activity coupled with a tolerable safety profile as treatment of patients with non–small cell lung cancer and EGFR exon 20 insertion mutations.
Follow-up Data for Olaparib Maintenance From SOLO-1 Provides Evidence of Consistent PFS Benefit in Ovarian CancerMarch 24th 2021
Five-year follow-up data from the SOLO-1 trial continue to show progression-free survival benefit of olaparib as maintenance therapy following platinum-based chemotherapy in the frontline setting for ovarian cancer.
Visible Residual Disease Following Interval Debulking in Ovarian Cancer Is Associated With Positive Outcomes With NiraparibMarch 20th 2021
Patients with newly diagnosed ovarian cancer who had interval debulking surgery and visible residual disease showed promising outcomes when treated with the PARP inhibitor niraparib, according to a post hoc analysis of a phase 3 clinical trial.
Study Results Appear to Support Larotrectinib Use in NTRK+ Lung CancerFebruary 20th 2021
Patients with advanced lung cancer whose tumors harbor an NTRK gene fusion with or without central nervous system metastases were found to have high response rates, durable responses, and extended survival benefit with larotrectinib.
Tivozanib Increased Time Without Symptoms of Disease, Toxicity for Patients with RCCFebruary 12th 2021
As third- or fourth-line therapy for patients with metastatic RCC, tivozanib hydrochloride demonstrated a statistically significant increased quality-adjusted time without symptoms of disease and toxicity compared with sorafenib.
Phase 3 DETECT III Study Suggests CTC Count to be Possible Biomarker for HER2-Directed Therapy in MBCDecember 11th 2020
The study found that favorable outcomes after treatment with lapatinib (Tykerb) were demonstrated by early declines in circulating tumor cell counts (CTCs) in patients with metastatic breast cancer who initially had HER2-negative primary tumors but positive HER2 CTCs.
Belantamab Mafodotin-Based Triplet Elicits High Response Rates, Appears Suitable in MyelomaDecember 8th 2020
The ongoing phase 1/2 DREAMM-6 trial found that the addition of belantamab mafodotin to bortezomib and dexamethasone elicited high response rates and a suitable safety profile in patients with relapsed or refractory multiple myeloma.
MEDI-570 Evokes Durable Reponses in Patients with R/R T-Cell LymphomasDecember 8th 2020
A phase 1 trial found that MEDI-570 demonstrated clinical activity with durable responses, as well as acceptable safety and tolerability in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma.